[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100497929":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":18,"locations":25,"responsibleParty":55,"collaborators":7,"id":58,"slug":7,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":7,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":7,"enrollmentInfo":66,"targetDuration":69,"studyType":70,"phases":7,"briefSummary":71,"conditions":72,"keywords":7,"overallStatus":28,"whyStopped":7,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Hospital Universitari de Bellvitge","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"PROCEDURE","Target Axillary Dissection","TAD after neoadjuvant chemotherapy and subsequent axillary lymph node dissection",[14],{"name":15,"affiliation":16,"role":17},"amparo Garcia-Tejedor, MDPhD","Instituto de Investigación Biomédica de Bellvitge (IDIBELL)","PRINCIPAL_INVESTIGATOR",[19],{"name":20,"role":21,"phone":22,"phoneExt":23,"email":24},"Amparo García-Tejedor, MDPhD","CONTACT","0034-932607702","2812","agarciat@bellvitgehospital.cat",[26,43],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Hospital de Bellvitge","RECRUITING","L'Hospitalet de Llobregat","Barcelona","08907","Spain",{"type":34,"coordinates":35},"Point",[36,37],2.10028,41.35967,{"lat":37,"lon":36},[40],{"name":41,"role":21,"phone":42,"phoneExt":7,"email":24},"Amparo Garcia-Tejedor, MDPhD","0034-660223417",{"facility":44,"status":28,"city":30,"state":7,"zip":45,"country":32,"cosmosGeoPoint":46,"geoPoint":50,"contacts":51},"Hospital Clínico y Provincial de Barcelona","08036",{"type":34,"coordinates":47},[48,49],2.15899,41.38879,{"lat":49,"lon":48},[52],{"name":53,"role":21,"phone":7,"phoneExt":7,"email":54},"Isaac Cebrecos, MD","CEBRECOS@clinic.cat",{"type":17,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Amparo Garcia-Tejedor","Clinical Professor","100497929",false,"NCT05763641","TAD After Chemotherapy in Locally Advanced Breast Cancer","Target Axillary Dissection After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer","Inclusion Criteria:\n\n* Axillary lymph node metastasis proven by cytology\n* Clinical or radiological N2a (at least 4 suspicious lymph nodes on axillary ultrasound at diagnosis)\n* Extensive T4 subsidiary to axillary lymphadenectomy according to current clinical criteria\n* Neoadjuvant chemotherapy\n\nExclusion Criteria:\n\n* cN3 verified by imaging tests\n* N2 due to internal mammary involvement (N2b).\n* Tumors whose surrogate molecular subtype is luminal A.\n* Patients undergoing neoadjuvant endocrine therapy\n* Patients with local recurrences and metastatic tumors.","ALL","18 Years",{"count":67,"type":68},162,"ESTIMATED","3 Years","OBSERVATIONAL","This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and\u002For cT4).",[73,74,75],"Sentinel Lymph Node","Breast Cancer","Locally Advanced","2025-09-08",{"date":78,"type":79},"2025-09-10","ACTUAL",{"date":81,"type":79},"2021-02-01",{"date":83,"type":68},"2026-06-01",{"name":5,"class":6},2]